Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBY: Abemaciclib +/- Hydroxychloroquine for Minimal Residual Disease in Breast Cancer
NCT04523857Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, hydroxychloroquine in breast cancer, sponsored by Abramson Cancer Center. Started Nov 2021; status: recruiting.
02
Drugs
abemaciclibhydroxychloroquine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04523857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523857.